227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
6 citations
,
April 1993 in “Journal of Dermatological Science” Certain substances can strongly inhibit DNA synthesis in hair cells.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
1 citations
,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
April 2017 in “Journal of Investigative Dermatology” Scientists can control how skin stem cells divide by using different treatments.
13 citations
,
January 2017 in “Molecules” Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.
1 citations
,
September 2015 Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
7 citations
,
March 2025 in “Cytotechnology”
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
November 2025 in “FEBS Open Bio” JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
24 citations
,
May 2009 in “The FASEB Journal” Akt2 and SGK3 are both important for normal hair growth and development.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
January 2018 in “Springer eBooks” Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
53 citations
,
October 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
57 citations
,
July 2000 in “Toxicology Letters” K6/ODC transgenic mice are effective for quickly identifying cancer-causing chemicals.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
April 2026 in “Amino Acids” Polyamines are crucial for skin tumor development, and inhibiting them can prevent tumors.